EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDADiscover the Best Stocks and Maximize Your Portfolio: See ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

The FDA cited issues with DexCom's response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7 ...

The announcement came after a quarter where DexCom reported a 7% increase in sales, though net income declined significantly alongside a reduction in earnings per share. During the past quarter ...

Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants. The maker ...

7.9% per year. Even after the forecast slowdown in growth, it seems obvious that DexCom is also expected to grow faster than the wider industry.

reached an agreement with DexCom to settle all outstanding patent disputes related to continuous glucose monitoring products. The agreement will dismiss all pending cases in courts and patent ...

DexCom (NASDAQ:DXCM), known for its continuous ... Conversely, the Non-GAAP operating income dropped 13.7% to $209.5 million, and the Non-GAAP EPS of $0.45 indicated a 10% year-over-year decline ...